Investigation of the Expression Levels of miR ‐383, miR ‐381, and miR ‐141 miRNAs as Diagnostic Biomarkers in Acute Myeloid Leukemia
International Journal of Laboratory Hematology · 2026
DOI: 10.1111/ijlh.70144 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2026. Verfasst von Mayyadah Ali Ahmed Al-Gburi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Myeloid, Acute, Biomarkers, Tumor, Gene Expression Regulation, Leukemic. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Acute myeloid leukemia (AML) is a clonal illness that is different in both medical and biological traits. Nonetheless, the genetic basis of this malignancy remains inadequately elucidated. MicroRNAs (miRNAs) are small noncoding RNAs that modify the expression of target mRNAs at both transcriptional and translational levels. In the past decade, miRNAs have evolved a unique mechanism in gene regulation, exhibiting varying expression throughout myeloid differentiation. This investigation examines the serum levels of miR‐383, miR‐381, and miR‐141 in AML and evaluates their diagnostic potential.
Methods
Serum samples from 110 AML patients and 110 normal individuals were evaluated using qRT‐PCR. Levels of expression were measured via the 2 −Δ Ct technique and normalized by U6. Diagnostic performance was assessed by the ROC curve analysis.
Results
MiR‐383 was significantly upregulated ( p = 0.0001), while miR‐381 and miR‐141 were downregulated ( p = 0.0002 and p = 0.0004, respectively) in AML patients. In addition, a considerable correlation was demonstrated between the expression levels of miR‐381 and subtype ( p = 0.02). In addition, the expression levels of miR‐141 and miR‐381 were positively correlated in AML patients ( r = 0.99, p ≤ 0.0001). The ROC analysis revealed strong potential of miR‐383 (AUC 0.87, 95% CI: 0.82–0.91), miR‐381 (AUC 0.71, 95% CI: 064–0.78), and miR‐141 (AUC 0.84, 95% CI: 0.79–0.89) as promising diagnostic biomarkers.
Conclusion
These miRNAs display distinct serum expression levels in AML, with miR‐383, miR‐381, and miR‐141 demonstrating potential as diagnostic biomarkers, necessitating additional confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran.
ORCID-Profile: Reza Safaralizadeh, Ali Rajabi
Zitieren
APA
Al-Gburi, M. A. A., Safaralizadeh, R., Rajabi, A., & Hosseinpour Feizi, M. (2026). Investigation of the Expression Levels of miR ‐383, miR ‐381, and miR ‐141 miRNAs as Diagnostic Biomarkers in Acute Myeloid Leukemia. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70144
Vancouver
Al-Gburi MAA, Safaralizadeh R, Rajabi A, Hosseinpour Feizi M. Investigation of the Expression Levels of miR ‐383, miR ‐381, and miR ‐141 miRNAs as Diagnostic Biomarkers in Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70144
BibTeX
@article{AlGburi2026,
author = {Al-Gburi, Mayyadah Ali Ahmed and Safaralizadeh, Reza and Rajabi, Ali and Hosseinpour Feizi, Mohammadali},
title = {Investigation of the Expression Levels of miR ‐383, miR ‐381, and miR ‐141 miRNAs as Diagnostic Biomarkers in Acute Myeloid Leukemia},
journal = {International Journal of Laboratory Hematology},
year = {2026},
doi = {10.1111/ijlh.70144}
}
EUVIMED